SELLAS completes enrollment of women for Phase 2 VADIS clinical trial
Category: #healthcare  By Akshay Kedari  Date: 2019-08-07
  • share
  • Twitter
  • Facebook
  • LinkedIn

SELLAS completes enrollment of women for Phase 2 VADIS clinical trial
  • This test would give opportunity to understand if NPS can induce immune response in patients with DCIS.
  • The VADIS outputs could tell the company about potential synergies among standard therapies and NPS in the women suffering from DCIS.

SELLAS Life Sciences Group, Inc., a biopharmaceutical firm focused on developing cancer immunotherapies, reportedly announced the completion of enrollment round in a randomized Phase 2 investigator-sponsored medical trial (IST) to assess nelipepimut-S (NPS) along with the granulocyte-macrophage colony-stimulating factor (GM-CSF) in women suffering from ductal carcinoma in situ (DCIS) in breasts that are HLA-A3+ or A2+ positive, show HER2 at IHC 3+, 2+ or 1+ levels, and are pre-menopausal or post-menopausal.

Chief Executive Officer and President of SELLAS, Angelos M. Stergiou, MD, ScD h.c., stated that company is thrilled to announce the finishing of registration for Phase 2 VADIS trial, a very vital point for a NPS clinical program of the company. The idea behind VADIS study is innovative as it would give important data and provide the company an opportunity to measure in a randomized and controlled setting if NPS can efficiently trigger an antitumor immune response in patients of DCIS.

Mr. Stergiou further stated that company believes NPS can be used as an initial stage treatment for breast cancer in women and expect to attain further insights through this study on the immunological mechanism that is responsible for NPS clinical activity.

Principal Investigator of the Phase 2 VADIS trial, Director of Breast Immuno-Oncology Program Dana-Farber/Brigham & Women’s Cancer Center, Director of Research, Breast Surgical Oncology Brigham and Women’s Hospital, Rob & Karen Hale Distinguished Chair in Surgical Oncology, Elizabeth A. Mittendorf, MD, PhD stated that the company is thrilled to complete enrollment of women for VADIS study, which would test for a range of sophisticated immunodynamic, molecular and histologic immune response markers following the treatment with NPS, which also includes the induction of HER2-specific epitope spreading and cytotoxic T Lymphocyte (CTL) with the former being the sign of medical efficacy for effective peptide vaccine.

Source Credit:

https://www.sellaslifesciences.com/investors/news/News-Details/2019/SELLAS-Announces-Completion-of-Enrollment-in-Randomized-Phase-2-VADIS-Trial-of-Nelipepimut-S-NPS-in-Women-with-Ductal-Carcinoma-In-Situ-DCIS-of-the-Breast/default.aspx

About Author

Akshay Kedari    

Akshay Kedari

Akshay holds a Bachelor’s degree in computer engineering. Despite having a penchant for software development and the like, Akshay took to writing as a career owing to his passion for the field. Presently, Akshay writes articles for itresearchbrief.com and a few oth...

Read More>>

More News By Akshay Kedari

Tencent Cloud boosts its footprint with launch of Indonesia data center
Tencent Cloud boosts its footprint with launch of Indonesia data center
By Akshay Kedari

Tencent Cloud has announced the launch of an Internet Data Center (IDC) in Indonesia, to provide cus...

U.S. FDA extends review period of Pfizer’s abrocitinib by three months
U.S. FDA extends review period of Pfizer’s abrocitinib by three months
By Akshay Kedari

The clinical tests of Pfizer’s drug included adolescents as well as adults with moderate-to-...

TIM Brazil picks Ceragon Networks to partake in TIP 5G OpenRAN trials
TIM Brazil picks Ceragon Networks to partake in TIP 5G OpenRAN trials
By Akshay Kedari

Ceragon Networks Ltd., an Israel-based networking equipment vendor, has reportedly been chosen by th...